Skip to search boxSkip to navigationSkip to main content

Characterization of a Novel Function-Blocking Antibody Targeted Against the Platelet P2Y1 Receptor

  • ,
  • Hari Priya Vemana
    ,
  • Fatima Z. Alshbool
    ,
  • Olivia A. Lin
    ,
  • Abdullah M. Alshehri
    ,
  • Payam Javaherizadeh
*Corresponding author for this work
  • Western University of Health Sciences
    ,
  • Loma Linda University Health
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

Objective-Platelet hyperactivity is associated with vascular disease and contributes to the genesis of thrombotic disorders. ADP plays an important role in platelet activation and activates platelets through 2 G-protein-coupled receptors, the Gq-coupled P2Y1 receptor (P2Y1R), and the Gi-coupled P2Y12 receptor. Although the involvement of the P2Y1R in thrombogenesis is well established, there are no antagonists that are currently available for clinical use. Approach and Results-Our goal is to determine whether a novel antibody targeting the ligand-binding domain, ie, second extracellular loop (EL2) of the P2Y1R (EL2Ab) could inhibit platelet function and protect against thrombogenesis. Our results revealed that the EL2Ab does indeed inhibit ADP-induced platelet aggregation, in a dose-dependent manner. Furthermore, EL2Ab was found to inhibit integrin GPIIb-IIIa activation, dense and α granule secretion, and phosphatidylserine exposure. These inhibitory effects translated into protection against thrombus formation, as evident by a prolonged time for occlusion in a FeCl3-induced thrombosis model, but this was accompanied by a prolonged tail bleeding time. We also observed a dose-dependent displacement of the radiolabeled P2Y1R antagonist [3H]MRS2500 from its ligand-binding site by EL2Ab. Conclusions-Collectively, our findings demonstrate that EL2Ab binds to and exhibits P2Y1R-dependent function-blocking activity in the context of platelets. These results add further evidence for a role of the P2Y1R in thrombosis and validate the concept that targeting it is a relevant alternative or complement to current antiplatelet strategies.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 637-644 (8 pages)

Journal (Volume, Issue Number)

Arteriosclerosis, thrombosis, and vascular biology (Volume 35, Issue 3)

Publication milestones

  • Published - 03/01/2015

Publication status

Published - 03/01/2015

ISSN

1079-5642

Publication IDs

  • Scopus: 84920885098
  • PubMed: 25593131

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
30
Citation count
19

Funding Details

FundersFunding number
NIH
-
NHLBI
R15HL115567